Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Orphan Medical's Busulfex Injection granted priority review

Oct. 8, 1998

Targeted Genetics initiates phase II trials for proprietary gene therapy compound

Oct. 8, 1998

Onconase and proteasome inhibitors have synergistic antitumor activity, even in resistant tumors

Oct. 8, 1998

ADIR presents two new series of ellipticine derivatives with improved profiles

Oct. 7, 1998

Antitumor agents with high potency and selectivity under evaluation at Shionogi

Oct. 6, 1998

Inex to focus internal R&D program on three cancer drug product candidates

Oct. 6, 1998

FDA approves anthracycline with orphan drug status for carcinoma in situ of the bladder

Oct. 5, 1998

Janssen terminates Avicidin agreement with NeoRx

Oct. 2, 1998

Onyx expands ONYX-015 clinical trials in pancreatic cancer

Oct. 2, 1998

Progesterone antagonists claimed for cancer, gynecological disorders by Meiji Seika

Oct. 1, 1998

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...